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Background: Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory
failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves
treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced
concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN)
beta-1a up-regulates the cell surface ecto-5′-nucleotidase cluster of differentiation 73 (CD73), which increases
adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study
in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality
rates were significantly lower in treated than in control patients.
Methods/design: In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of
recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients
will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days
and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take
place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at
28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-
cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic
assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of
life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a
reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be
conducted in 70–80 centers in nine countries across Europe.
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Discussion: There are no effective specific treatments for patients with ARDS and mortality rates remain high.
The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent,
FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS.
Trial registration: European Union Clinical Trials Register, no: 2014-005260-15. Registered on 15 July 2017.
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Acute respiratory distress syndrome (ARDS)
ARDS is a serious clinical disorder which follows a
variety of severe lung insults including, among others,
pneumonia, aspiration of gastric contents, non-
pulmonary sepsis and major trauma. ARDS is a type
of acute diffuse lung injury, characterized by acute
lung inflammation with injury to the endothelial
barriers and alveolar epithelium of the lung, increased
pulmonary vascular permeability, and protein-rich
pulmonary edema leading to acute respiratory failure.
In the Berlin definition of ARDS (Table 1) [1], sever-
ity is graded from mild, through moderate, to severe
ARDS.
Although mortality from ARDS has decreased in the
last decade due to improvements in supportive care and
in the treatment of underlying conditions [2, 3], it re-
mains high at levels of 20 to 40% across all severities
and even higher when associated with dysfunction in
other organs [1, 2, 4, 5].
ARDS is also costly in health economics terms.
Patients with ARDS consume significantly more re-
sources than other groups of critically ill patients [6] be-
cause they have longer intensive care unit (ICU) and
hospital stays. The quality of life (QoL) of these patients
may also be significantly impacted [7], with 35% of pa-
tients with moderate or severe ARDS unable to return
to work 24 months after hospital discharge [8, 9].
There are currently no approved pharmacological
therapies for ARDS and treatment relies on management
of the underlying cause and supportive care.Table 1 The Berlin ARDS definition [1]
Characteristic Mild ARDS
Timing Acute onset within 1 week of a known clinical
Hypoxemia PaO2/FiO2
> 200– ≤ 300 mmHg
with PEEP or CPAP ≥ 5 cmH2O
Origin of edema Respiratory failure associated with known ARDS
An objective assessment of cardiac failure or flu
Radiological abnormalities
(chest X-ray or CT scan)
Bilateral opacities not fully explained by effusion
ARDS acute respiratory distress syndrome, CPAP continuous positive airway pressure
inspired oxygen, PEEP positive end-expiratory pressureInterferon beta-1a
A key pathophysiological feature of ARDS is increased
vascular leakage, which has been suggested to be related
to a lack of local adenosine which acts to enhance endo-
thelial barrier function [10]. Therefore, any biological
substances that can increase local adenosine levels may
reduce vascular leakage and thus be of benefit in ARDS.
Such a substance is cluster of differentiation 73 (CD73)
– a cell surface ecto-5′-nucleotidase enzyme that con-
verts soluble AMP into locally active adenosine [11]. In-
terferons, such as interferon (IFN) beta-1a, have been
shown to up-regulate CD73 and could, therefore, repre-
sent a potential treatment for ARDS. Preclinical studies
have shown that CD73 expression on endothelial cells is
up-regulated by IFN beta-1a treatment in a time- and
dose-dependent fashion [12–14]. Furthermore, IFN
beta-1a treatment has been shown to prevent leakage in
animal models of acute lung injury (ALI) [12]. Enhanced
adenosine production also controls leukocyte infiltration
[15], thus reducing the escalation of inflammation in the
lungs.
Recombinant human IFN beta-1a (FP-1201-lyo) was
assessed for the treatment of ALI and ARDS, as defined
using the AECC definitions [16], in a phase I/II study
[13]. This open-label study, conducted in eight ICUs in
the UK, included 37 patients with ALI/ARDS and the
optimum tolerated dose of FP-1201-lyo was shown to be
10 μg daily. The primary efficacy endpoint, 28-day mor-
tality, was 8% in the treated patients compared to 32% in
the control patients; treatment with FP-1201-lyo was as-
sociated with an 81% reduction in the odds of death atModerate ARDS Severe ARDS
insult or new or worsening respiratory symptoms
PaO2/FiO2
> 100– ≤ 200 mmHg
with PEEP ≥ 5 cmH2O
PaO2/FiO2
≤ 100 mmHg
with PEEP ≥ 5 cmH2O
risk factors and not fully explained by cardiac failure or fluid overload.
id overload is needed if no ARDS risk factors are present
s, nodules, masses or lobar/lung collapse
, CT computed tomography, PaO2/FiO2 partial pressure of oxygen/fraction of
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[13]. The beneficial effects on outcomes were still
present at 6-month follow-up. Pyrexia was the most
common drug-related treatment-emergent adverse event
in the study. All pyrexia events resolved rapidly without
sequelae. There were no other safety concerns during
the study period. Subcutaneous recombinant human
IFN beta-1a is already an approved treatment for pa-
tients with relapsing-remitting multiple sclerosis and its
safety profile in such patients is well characterized.
Following the promising results of the phase I/II study
[13], the current phase III study was designed to confirm the
beneficial effects of FP-1201-lyo in a larger population of pa-
tients with ARDS. Herein, we describe the final protocol
(version 6.0; 29 Aug 2017) for this study, written in accord-
ance with the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines. The SPIRIT
Checklist is provided as Additional file 1.
Methods/design
This is a multicenter, phase III, double-blind, random-
ized, parallel-group comparison study of the efficacy and
safety of FP-1201-lyo compared with placebo in adult
patients with moderate or severe ARDS. The study will
be conducted in 70–80 centers in nine European
countries. The study is registered on the European
Union Clinical Trials Register, no: 2014-005260-15.
We will conduct the study in accordance with the
principles of the Declaration of Helsinki [17] and the
International Conference on Harmonization (ICH)
guidelines on Good Clinical Practice. The Local Ethics
Committee for each center will approve the study
(approvals already in place shown in Additional file 2).
Study population
Study site investigators will screen patients in the ICU
for eligibility and obtain written informed consent. Study
sites will review all ICU patients daily in order to iden-
tify potential patients.
Inclusion criteria include:
1. Patient is aged ≥ 18 years
2. Patient's trachea is intubated and they are receiving
mechanical ventilation
3. Patient has a diagnosis of moderate or severe ARDS
according to the Berlin definition of ARDS [1]:
(a)Acute onset of respiratory failure within 1 week
of a known clinical insult or new or worsening
respiratory symptoms
(b)Respiratory failure associated with known ARDS
risk factors and not fully explained by either
cardiac failure or fluid overload (an objective
assessment of cardiac failure or fluid overload is
needed if no risk factors for ARDS are present)(c)Radiological abnormalities on chest X-ray or on
computed tomography (CT) scan, i.e., bilateral
opacities that are not fully explained by effusions,
nodules, masses or lobar/lung collapse
(d)Hypoxemia:
 Moderate ARDS: PaO2/FiO2 > 100 mmHg
(>13.3 kPa) to ≤ 200 mmHg (≤ 26.6 kPa) with
positive end-expiratory pressure (PEEP) ≥ 5
cmH2O
 Severe ARDS: PaO2/FiO2 ≤ 100 mmHg (≤ 13.3
kPa) with PEEP ≥ 5 cmH2O
4. The radiological and hypoxemia criteria (3 (c)
and (d)) must occur within the same 24-h
period. The time of onset of ARDS is defined
as the time when the last of these two ARDS
criteria is met
5. Administration of the first dose of study drug
must be planned to take place within 48 h of
moderate or severe ARDS diagnosis
6. A signed written informed consent form from the
patient or the patient’s personal legal
representative or a professional legal
representative must be availableExclusion criteria include:
 Woman known to be pregnant, lactating or with a
positive (urine or serum test) or indeterminate
(serum test) pregnancy test
 Patient simultaneously taking part in another
pharmacotherapy protocol
 Patient not expected to survive for 24 h
 Patient has an underlying clinical condition where,
in the opinion of the investigator, it would be
extremely unlikely that the patient would be able to
come off ventilation, e.g., motor neurone disease,
Duchenne muscular dystrophy, or rapidly
progressive interstitial pulmonary fibrosis
 Patient has severe chronic obstructive pulmonary
disease (COPD) requiring long-term home oxygen
therapy or mechanical ventilation (non-invasive
ventilation or via tracheotomy) except for continuous
positive airway pressure (CPAP) or bi-level positive
airway pressure (BIPAP) used solely for sleep-
disordered breathing
 Patient has congestive heart failure, defined as New
York Heart Association class IV
 Patient has acute left ventricular failure
 Patient has liver failure (Child-Pugh grade C)
 Patient has received any prior IFN
 Patient has known hypersensitivity to natural or
recombinant IFN beta or to any of the excipients
 Patient is receiving renal dialysis therapy for chronic
renal failure
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oxygenation, high-frequency oscillatory ventilation
(HFOV) or any form of extracorporeal lung support
 Patient has had any form of mechanical ventilation
(invasive or non-invasive, excluding CPAP alone) for
longer than 48 h prior to the diagnosis of ARDS.
Non-invasive ventilation has to be continuously
applied for at least 12 h per day in these 48 h
 Patient has burns to ≥ 15% of their total body
surface area
Study drug
All study drugs will be supplied in identical vials and will be
similar in color and appearance, enabling double-blind con-
ditions. The powdered FP-1201-lyo or placebo (powdered
lyophilisate) will be diluted in water for injection near the
patient/in the ICU using a MixJect® transfer device (West
Pharmaceutical Services GmbH, Germany/Medimop Med-
ical Projects, Ra’anana, Israel). Once prepared, the dose
must be administered to the patient immediately. The di-
luted FP-1201-lyo or placebo will be administered as an
intravenous bolus injection via a central or peripheral line.
The injection will be followed with a 5-mL flush of sterile
saline. FP-1201-lyo and placebo injections will be given
once daily for 6 days. The injection will be given at the
same time each day ± 1 h providing the patient’s condition
allows this. If for any reason this is not possible, the treat-
ment window may be extended by up to 4 h. Subsequent
doses should not be delayed and should revert to the ori-
ginal time schedule. No dose modifications or temporary
cessations of study drug administration are allowed. If a
delay beyond the 4-h window described above is required,
the patient must be withdrawn from study drug but all data
must continue to be collected per protocol.
Study protocol
Local study investigators will use an interactive, web-
response system to randomize the patients on a 1:1 basis
using country and ARDS severity as stratification parame-
ters. To ensure that conclusions are not dominated by
data from a small number of centers, and also to obtain a
broad spread of patients and centers within the con-
straints of the inclusion/exclusion criteria, each center will
be allowed to include up to, but no more than, 30 patients.
Study investigators at each center will enter all study-
related data using electronic Case Report Forms (e-CRFs).
Following randomization, patients will receive
FP-1201-lyo 10 μg or placebo administered intravenously
as a bolus each day for 6 days. The first dose of drug
must be administered within 48 h after diagnosis of
moderate or severe ARDS. The APACHE II score [18]
will be calculated within 24 h of ICU admission. Patients
will undergo daily assessments while in the ICU for a
maximum of 28 days to include blood sampling forhematology and biochemical variables, CD73 and
myxovirus resistance protein A (MxA) concentrations;
dipstick urinalysis; PaO2/FiO2; fluid balance; vital
signs (heart rate, respiratory rate, arterial blood
pressure, body temperature); and Sequential Organ
Failure Assessment (SOFA) score variables [19]. The
SOFA score will be calculated pre-dose on day 1,
then daily up to day 14, at day 21 and at day 28
while the patient is in the ICU, based on worst daily
values. Concomitant medications will be recorded.
Blood samples for IFN beta-1a neutralizing antibodies
will be taken 1 h prior to the first dose and on the
day that the patient leaves the ICU or on day 28 if
the patient is still on the ICU. Long-term follow-up
will occur at day 90 (visit or telephone contact) and
day 180. On day 180 (± 14 days), the EuroQol
5-Dimensions 3-Levels questionnaire (EQ-5D-3 L),
the forced expiratory volume in 1 s (FEV1) and the 6-
minute Walk Test (6MWT) will be assessed. The
Clinical Study Report (CSR) will be completed once
all the unblinded data up to day 90 have been
collected and verified and analyzed according to the
statistical plan. Long-term and extended follow-ups
will take place at day 180 and day 360 and will
include assessments of 6- and 12-month mortality,
EQ-5D-3 L, 6MWT and FEV1. The extended follow-
up data will be reported as addendums to the CSR.
During the long-term and extended follow-up periods,
and after the end of the extended follow-up visit,
patient care will follow normal hospital procedures.
The study will be completed when the final patient
completes their day 360 study assessment. No interim
analyses are planned between days 1–180. The study
design is summarized in Fig. 1 and timings of assess-
ments and procedures detailed in Fig. 2.General patient management
Apart from administration of the study drug, patients
will be managed according to best practice as detailed in
Additional file 3. In particular, mechanical ventilation
should be provided using a lung-protective ventilation
approach incorporating a low-tidal-volume strategy [20].
Any mode of ventilation capable of delivering the
prescribed tidal volume (6 mL/kg predicted body weight
(PBW) ± 2 mL/kg) within the pressure limitation (plat-
eau pressure limitation ≤ 30 cmH2O) may be used. The
use of extracorporeal membrane oxygenation (ECMO) is
allowed as rescue therapy. Weaning should follow local
ICU protocols if available or the guidelines given in
Additional file 3. Fluid management should be unre-
stricted during episodes of shock, but in patients not in
shock, a conservative fluid approach should be adopted
(see the table in Additional file 3) [21].
FP-1201-
lyo 10 µg
Placebo 
-48 h pre-dose on D1 D1 D6 D7 D28 D90 D180 D360
Screening Randomization Double-
blind 
treatment 
period
Short-
term FU
Long-term FU Extended FU
Baseline
includes pre-dose on D1a
Daily assessments up to 
D28 while in ICU 
End of Study
CSR Addendum 
to CSR
Addendum to 
CSR
Fig. 1 Study design. aNot more than 48 h may elapse between confirmation of moderate or severe acute respiratory distress syndrome (ARDS)
during screening and administration of the first dose of study drug on day 1. Once eligibility has been met, randomization can occur during
screening or pre-dose on day 1
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All serious adverse events (SAEs) that occur between the
signing of informed consent and day 28 will be recorded.
Events occurring after day 28 will be reported only if
they are considered to be causally related to the investi-
gational drug; however, all deaths up to day 180 will be
reported as SAEs. An SAE is defined as any untoward
medical occurrence that at any dose:
 Results in death
 Is life-threatening
 Requires inpatient hospitalization or prolongation of
existing hospitalization
 Results in persistent or significant disability or
incapacity
 Causes a congenital anomaly or birth defect
 Is an important medical event that may not be
immediately life-threatening or result in death or
hospitalization but that may jeopardize the patient
or require intervention to prevent one of the above
outcomes
The study design incorporates an Independent Data
Monitoring Committee (IDMC) comprising four members:
one independent biostatistician and three senior clinicians
with significant experience in ARDS who are not involved
in the study. The IDMC will review ongoing safety data in
an unblinded manner with meetings scheduled to take
place after the data has been received from the last patient
of approximately 30, 60, 120, 200 and 300 patients who
either have completed 14 days in the study following their
first dose of study medication or have been withdrawn for
any reason (including death). At each meeting, the IDMC
will make a blinded recommendation to the sponsorregarding the study to continue without change, modify
study or enrollment to be placed on hold, or study
termination.
Outcome measurements
The primary endpoint is a composite of death and days free
of mechanical ventilation within 28 days among survivors. A
patient will be considered as ventilator free after two con-
secutive calendar days of unassisted breathing, defined as
breathing spontaneously with a face mask, nasal prong oxy-
gen or room air; T-piece breathing; tracheostomy mask
breathing; CPAP ≤ 5 cmH2O without pressure support or
intermittent mandatory ventilation assistance; or use of
CPAP or BIPAP solely for sleep apnea management.
Secondary endpoints can be divided into efficacy,
safety and exploratory categories.
Efficacy
 All-cause mortality assessed at 28, 90, 180 and
360 days
 Days free of organ failure (assessed using the SOFA
score), days free of renal support, days free of
vasoactive support, days free of mechanical
ventilation, number of intensive care unit (ICU)-free
days, assessed at day 28 (or on the last day in the
ICU if the patient leaves the ICU before day 28)
 Length of hospital stay
 Immunogenicity of FP-1201-lyo assessed by change
in level of neutralizing antibodies to IFN beta-1a
between baseline and day 28 (or on the last day in
the ICU if the patient leaves the ICU before day 28)
 FEV1, neurological functioning (6MWT) and QoL
(EQ-5D-3 L) assessed at 180 and 360 days
EQ-5D-3L, FEV1 and 6MWT EQ-
5D-3Li
X X
PaO2/FiO2 X X X X X X
Blood sample: CD73 and PIM Xh X X
Pharmacoeconomics X X
Physical examination X X X o
Vital signs Xj X X X X X X o
ECG X D7 X X
Hematology, chemistry, urinalysisk Xj X X X X X X o
Pregnancy test in women of 
childbearing potential
X
Previous and concomitant 
medications and therapies
Xl X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -X
Adverse events Xm X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X Xn Xn Xn
Blood sample: genetic analysis 
(requires separate consent)
X - - - - - - - - - - - - - 1 sample at any time while in ICU - - - - - - - - -X
Screen
-ing 
period
Double-blind treatment 
period
Days 1-6
Short-term follow-up until D28 or 
discharge from ICU (whichever is earlier)
Long-term 
follow-up
Extended 
follow-up
Baseline period D7 D28
Procedure 48 ha D1 
pre-
dose
D1 D2 D6 D7 D14 D15
D27
Last day 
in ICUb
D28c D90d
+14 days
D180 
+14 days
D360     
+14 days
Informed consent X
A
dm
in
is
tr
at
io
n 
of
 s
tu
dy
 d
ru
g
Medical history X
Demographic details X
Documentation of chest X-ray or 
CT scan
X
Inclusion/exclusion criteria X Xe
Randomization Xf
Administration of study drug X X
Survival X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X
On mechanical ventilation? (Y/N) X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X
In ICU/in hospital? (Y/N) X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X
SOFA X X X D21 X X o
GCS (for SOFA and APACHE II) X X X X D21 X X o
APACHE II X g
Renal and vasoactive support? 
(Y/N)
X X - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X
Blood sample: IFN beta-1a 
neutralising antibodies
Xh X X
Blood sample: MxA Xh X X 
Fig. 2 Schedule of procedures. aNo more than 48 hours may elapse between confirmation of moderate or severe ARDS and administration of
the first dose of study drug. bThese assessments will be done on the day the patient leaves the ICU, which will either be on D28 or earlier, according
to the clinical progress of the patient. If the patient is still in the ICU on D28, the next visit or telephone contact will be at D90. If a patient leaves the
ICU before D28, the survival status and other endpoints must be assessed on D28. cD28 procedures apply for patients leaving the ICU before D28 and
for patients withdrawing from the study before D28. For patients withdrawing from the study before D28 a sample should be taken for neutralizing
antibodies on the day they leave the ICU. dD90 can either be a visit or telephone contact. eReconfirm inclusion/exclusion criteria before dosing,
including that patient requires mechanical ventilation and is in the ICU. fRandomize after consent obtained and once eligibility criteria confirmed.
gWithin 24 hours of ICU admission. h1 hour pre-dose. iBaseline EQ-5D-3L to be obtained from relatives and checked later with patient. jFor APACHE II
scoring. kSamples should be taken in the morning between 04:00 and 10:00. lMedicines and therapies in previous month. mAdverse events will be
recorded after informed consent is obtained. nDeaths are reported as SAE. 0if it is possible to be performed by the investigator. APACHE II Acute
Physiology and Chronic Health Evaluation, CD Cluster of differentiation, CT Computerized tomography, D Study day, ECG Electrocardiogram, EQ-5D-3L
EuroQol 5-Dimensions 3-Levels questionnaire, FEV1 Forced expiratory volume in 1 second, GCS Glasgow Coma Scale, ICU Intensive care unit, IFN
Interferon, MxA Myxovirus resistance protein A, PaO2/FiO2 Partial pressure of oxygen/fraction of inspired oxygen, PIM Potential inflammatory marker,
SOFA Sequential Organ Failure Assessment, 6MWT 6-minute walk test
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 Adverse events (assessed by seriousness, intensity
and causality) up to day 28, and up to day 360 if the
investigator considers that there is a causal
relationship with the study drug
 Physical examination, vital signs and laboratory
results up to day 28 (or last day in ICU if patient
leaves the ICU earlier)
Exploratory
 Gas exchange (partial pressure of oxygen/fraction of
inspired oxygen (PaO2/FiO2) ratio) during
mechanical ventilation as an indicator of improving
lung function on treatment. This categorical
endpoint is defined as improvement, no change, or
worsening in terms of gas exchange (PaO2/FiO2
ratio) from baseline to day 28
 Change in the concentration of CD73 and MxA
and potential inflammatory markers, including
interleukin-6 and interleukin-8, from baseline to
day 14
 Genetic testing to identify factors that may be
involved in the response or nonresponse of diseases to
FP-1201-lyo. In patients who have provided separate
consent for this procedure, a 10-mL blood sample for
deoxyribonucleic acid (DNA) extraction will be
collected at any time during the patient’s ICU stay. All
such samples will be destroyed 15 years after completion
of the study. If the patient withdraws the consent, the
sample will be destroyed immediately
Data collection and management
The sponsor or sponsor’s designee will conduct a site
visit to each study center to verify the qualifications
of each investigator, inspect the site facilities and
inform the investigator of their responsibilities and
the procedures for ensuring adequate and correct
documentation.
The investigators will be given access to an online,
web-based, electronic data-capture system that is
compliant with US Food and Drug Administration
Title 21 Code of Federal Regulations Part 11. Access
rights to the electronic data-capture system will be
carefully controlled and configured according to each
individual’s role throughout the study. Computerized
data-check programs and manual checks will identify
any data discrepancies for resolution. All discrepancies
must be resolved online directly by the investigator. Only
the investigator will be able to enter and correct data in
the e-CRF.
All study findings and documents will be regarded as
confidential. Patients will be identified on the e-CRF bytheir patient number and/or birth date, not by name.
Documents that identify the patient must be maintained
in confidence by the investigator so that the anonymity
of participating patients is ensured.
During the study, the Contract Research Organization
(CRO) will make regular site visits to review protocol
compliance, conduct source data verification, assess drug
accountability and management, assess laboratory proce-
dures and ensure that the study is being conducted accord-
ing to pertinent regulatory and protocol requirements.
The study blind should only be broken in a medical
emergency (where knowledge of the study drug received
would affect the treatment of the emergency) or as a
regulatory requirement (e.g., for serious adverse events
or death).
Withdrawal of consent
Patients may withdraw from the study at any time
and for any reason and such a decision will not affect
the ongoing care given to the patient. Data recorded
up to the point of withdrawal will be included in the
study analyses, unless consent for use of the data has
also been withdrawn. If a patient requests termination
of the administration of the study drug during the
treatment period, then the administration of the study
drug will be stopped but the patient will continue in
the study and all follow-up assessments will be
performed. If a patient withdraws consent during or
after the treatment period then no further active
study assessments will be performed from that time
point. However, permission will be sought to access
the patient’s medical records to obtain data relevant
to the study (e.g., outcome status).
Statistical analysis
For 90% power and a two-sided Mann-Whitney U test
at the significance level of 0.05, a total of 272 patients
are required based on the following assumptions:
 Mortality rate of 30% in the control group and 15%
in the FP-1201-lyo group at day 28
 20% of patients survive but with zero ventilator-free
days in the control group
 A mean difference (FP-1201-lyo minus control) of
3.0 days in mean ventilator-free days where patients
who die are assigned a score of 0
However, assuming that 5% of patients will drop out
and a further 4% of the remaining patients will not be
evaluable for the efficacy analysis, we plan to randomize
300 patients.
The full analysis set (FAS) will consist of all random-
ized and treated patients. The per-protocol set (PPS) will
consist of patients in the FAS excluding those with
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analyses for the primary and secondary endpoints on
both the FAS and PPS.
The safety set will consist of all patients who receive at
least one dose of the study drug. The safety and tolerability
analyses will be based on this analysis set. A patient who re-
ceives the wrong treatment according to the randomization
will be analyzed for safety and tolerability in the treatment
group corresponding to the treatment received.
The non-parametric analysis of the primary composite
endpoint, any cause of death at day 28 and days free of
mechanical ventilation within 28 days among survivors
(VFDsurv), will use a scoring scheme with patients who do
better getting a higher score. We will assign a VFDsurv
score of − 1 to all patients who die before 28 days. For those
patients who survive to day 28 the VFDsurv score will be
equal to the number of VFDs calculated according to the
above definition. The statistical method for group compari-
son of this endpoint will be based on the van Elteren test
adjusting for the country, ARDS severity and key baseline
characteristics. The statistical methodology for the scoring
scheme is as set down in Finkelstein and Schoenfeld [22].
In general, data will not be imputed for the primary ef-
ficacy analysis or the safety analysis. For other efficacy
analyses, where relevant, imputations will use the last-
observation-carried-forward method. All statistical tests
will be two-sided and will be performed at the signifi-
cance level of 0.05.
Discussion
At present, there is no approved pharmacological treatment
for ARDS so there is no possible comparator for studies of
potential ARDS therapies. The only currently available
treatment for ARDS patients is supportive care. Hence, the
current approach to ARDS study design should be to show
superiority of the investigated study drug over current
standard of care. The study drug will be used in addition to
supportive care and, therefore, it is most appropriate to use
placebo as a comparator. The pathogenesis of ARDS can be
divided into three distinct phases – acute (days 1–6), sub-
acute (days 7–14) and chronic (day 15 +). Almost all
patients who fail to improve or deteriorate after 1 week of
ventilation have evidence of lung fibrosis, so that adminis-
tering treatment beyond 6 days would add little value to
patients included in this study. A 6-day dosing regimen
was, therefore, selected as the optimal treatment regimen.
The composite endpoint was chosen as likely to be
more sensitive than just 28-day mortality to detect an
effect signal. In addition, this study has a double-blind
design, so the decision to wean the patient from mech-
anical ventilation should not be influenced by the treat-
ment group. Owing to the randomization procedure and
the double-blind nature of this study, the potential bias
of the study results is minimized.If this study demonstrates improved outcomes in patients
receiving FP-1201-lyo, this agent will represent the first
specific pharmacological treatment for ARDS and a major
advance in the management of these patients.
Trial status
The first patient was enrolled on 28 December 2015 and
the study is ongoing.
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